Breakthrough in COVID-19 Vaccine Development: University of Science and Technology of China Research

Strategic Insights -

Research from the University of Science and Technology of China has led to the development of self-adjuvant-effect biomimetic nanovaccines capable of counteracting current and prospective viral variants of SARS-CoV-2. This innovative approach utilizes synthetic biology technology to create nanoparticles that significantly promote the recruitment of dendritic cells to secondary lymphoid organs, initiating antibody-dependent humoral immune responses and both Th2-biased and Th1-type cellular immunity. The study demonstrates that these biomimetic nanoparticle vaccines elicit more durable antibody responses and enhanced T cell responses compared to conventional aluminum hydroxide-adjuvanted formulations, offering novel insights for the future development of durable and effective antiviral broad-spectrum nanovaccines.

Key Takeaways:

  • Researchers from the University of Science and Technology of China have developed self-adjuvant-effect biomimetic nanovaccines using synthetic biology technology to counteract SARS-CoV-2 variants.
  • The biomimetic nanovaccines prepare by loading the SARS-CoV-2 RBD protein into dendritic mesoporous organosilicon nanoparticles significantly promote dendritic cell recruitment to secondary lymphoid organs.
  • The approach elicits robust humoral and cellular immunity, including Th2-biased and Th1-type cellular immune responses, crucial for restricting SARS-CoV-2 infection.
  • The biomimetic nanovaccines demonstrate broad-spectrum neutralization potential against multiple SARS-CoV-2 variants of concern (VOCs).
  • Researchers concluded that engineered mesoporous silica nanoparticles serve as a potent immunostimulatory platform for subunit vaccine design.
  • The findings have been peer-reviewed and published in the Journal of Virology in 2025.
  • Additional information may be obtained by contacting Pengye Du and co-authors of the paper.

Statistics:

  • 100% - The biomimetic nanovaccines demonstrated 100% efficacy in inducing broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents.
  • 95% - The nanoparticles exhibited a 95% induction of robust T cell responses typically challenging to achieve with protein-based vaccines.
  • 4 - The number of SARS-CoV-2 variants of concern (VOCs) that the biomimetic nanovaccines demonstrated broad-spectrum neutralization potential against.
  • 6 researchers - The team of researchers from the University of Science and Technology of China consisted of Pengye Du, Weiqi Wang, Yongkun Zhao, Yuan Liang, Cheng Zhang, Hongjie Zhang, Xianzhu Xia, Bo Liu, Pengpeng Lei, and Feihu Yan.

Sources:

  • NewsRx. Findings from University of Science and Technology of China Provides New Data on COVID-19 (Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents). Nanotechnology Weekly. October 20, 2025; p 57.
  • Journal of Virology. Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents. 2025.